Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5559611 | 0.84 | ERN1 (0.40) | TNFRSF1AERN1 | |
| SCHEMBL6040634 | 0.81 | ERN1 (0.40) | TNFRSF1AERN1 | |
| SCHEMBL6040854 | 0.78 | TNFRSF1A (0.35) | TNFRSF1AERN1 | |
| SCHEMBL6040641 | 0.74 | TNFRSF1A (0.35) | TNFRSF1AERN1 | |
| SCHEMBL5565722 | 0.72 | ERN1 (0.47) | TNFRSF1AERN1 | |
| SCHEMBL5560733 | 0.71 | TNFRSF1A (0.57) | TNFRSF1AERN1 | |
| SCHEMBL6040583 | 0.69 | ERN1 (0.47) | TNFRSF1AERN1 | |
| SCHEMBL5605276 | 0.68 | — | — | |
| SCHEMBL5559926 | 0.68 | ERN1 (0.49) | TNFRSF1AERN1 | |
| SCHEMBL6040679 | 0.68 | TNFRSF1A (0.52) | TNFRSF1AERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHEROGENICS, INC. (US) | 2007-04-26 | — | — | US | disclosed |
| US-7173129-B2 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | ATHERO GENICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | CRABTREE ACQUISITION CO, LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2004108094-A2 | SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES | ATHEROGENICS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049236-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | TNFRSF1A 3941/4885ERN1 2156/4885 |
| US-20070093453-A1 | Sulfonamide-substituted chalcone derivatives and their use to treat diseases | STS, HPSE, SULT1E1 | TNFRSF1A 3941/4885ERN1 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.